J W wrote:
> Temsirolimus also called (CCI-779) is another drug showing promise in
> renal cancers. I realize access to drugs may be somewhat limited in NZ
> but if you are in a position to travel and your husband is physically
> able.
NZ has sirolimus for kidney transplant patients, so much have access to
Temsirolimus.
http://www.medscape.com/viewarticle/535654
The investigators initiated a phase 3 study in 626 patients with advanced
renal cell carcinoma who had had no prior systemic therapy. Eligible
patients had at least 3 of 6 factors indicating a poor risk, including the 5
Motzer criteria and at least 1 metastatic site.
The investigators then randomized patients in a 1:1:1 manner to receive
subcutaneous injections of interferon-alfa at a dose of up to 18 MU 3 times
weekly; intravenous temsirolimus at a dose of 25 mg once weekly; or
intravenous temsirolimus at a dose of 15 mg once weekly and subcutaneous
interferon-alfa at a dose of 6 MU 3 times weekly.
The investigators wanted to compare patients' overall survival with
interferon-alfa vs temsirolimus.
Of a total of 626 patients, 442 died during the study period.
Patients in the temsirolimus monotherapy group lived a median of 10.9
months, while those on interferon-alfa lived a median of 7.3 months and
those on combination therapy lived an average of 8.4 months; the latter 2
groups had statistically similar overall survival rates.
The 3 most frequently occurring grade 3 or higher adverse events were as
follows:
* Asthenia, at rates of 27% in the interferon-alfa monotherapy group,
12% in the temsirolimus monotherapy group, and 30% in the combination group.
* Anemia, at rates of 24% in the interferon-alfa monotherapy group, 21%
in the temsirolimus monotherapy group, and 39% in the combination therapy
group.
* Dyspnea, at rates of 8% in the interferon-alfa monotherapy group, 9%
in the temsirolimus monotherapy group, 11% in the combination-therapy group.
For this study on temsirolimus, several questions are worth exploring. If
the drug were used in a population with a better prognosis, would it also be
favorable? Usually, these therapies are more active in more favorable
populations. said Peter Ravdin, MD, who was not involved in the study.
I'd also like to know if temsirolimus has a place in adjuvant chemotherapy
after resection. We don't have anything that's effective at this point."